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34 percutaneous implantable valves; one patient underwent the implantation of both, a
mitral and an aortic valve device during the same pracedure. Both, the Edwards-Sa-
pien and the CoreValve devices were used. Outcomes were evaluated using the VARC
2 criteria.
Results: Valve-in-Valve in the aortic position (N¼23): mean age of patients was 81.4
 5.9 years. The CoreValve and the Edwards-Sapien valve devices were used in
91.3% and 8.7% of patients, respectively. The CoreValve device was implanted via
the trans-axillar route in 3 cases and via trans-femoral route in 18 cases. The trans-
apical route was used in both Edwards-Sapien implantations. Procedural success was
achieved in 100% of cases. One month and one year survival rates were 100% and
90%; respectively. At one month follow up, 95.7% of patients were in NYHA I/II.
Valve-in-Valve in the mitral position (N¼10): mean age of patients was 73.6  15
years. All the procedures were performed with the Edwards-Sapien device via the
trans-apical route. Procedural success was achieved in 100% of cases. One month and
one year survival rates were 90% and 80%; respectively. At one month follow up,
100% of patients were in NYHA I/II. Valve-in-Valve in the tricuspid position (N¼1):
A 78 year-old patient NYHA IV, was treated with the successful trans-femoral vein
implantation of an Edwards-Sapien 29mm valve within a severely stenotic bio-
prosthetic Handcock 31mm valve. The procedure went uneventful. At one month
follow up the patient was in NYHA II. Pre- and post- peak and mean trans-valvular
gradients were 26/16 and 6/3 mmHg, respectively.
Conclusions: In our experience, the Valve-in-Valve procedure for the treatment of
failed bio-prosthetic valves, using multiple access techniques and available devices,
led to signiﬁcant symptomatic improvement, low peri-procedural morbidity and low
mortality rates.
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Background: Elevated levels of natriuretic peptides are associated with adverse
outcome across a wide spectrum of cardiovascular diseases. However, cut-off values
differ according to age, gender, and body weight. We studied the prognostic value of
plasma N-terminal pro-brain natriuretic peptide (NT-proBNP)-ratio, which is inde-
pendent of individual cut-off levels, in predicting mortality in patients undergoing
transcatheter aortic valve replacement (TAVR).
Methods: Out of 350 consecutive TAVR patients, 244 patients with pre-procedural
NT-proBNP levels were included in the analysis, and the predictive value of NT-
proBNP-ratio (measured NT-proBNP/maximal normal NT-proBNP values speciﬁc for
age and gender) on all-cause-mortality was assessed in a multivariate model.
Results: Median BNP-ratio was 4.2 [interquartile range 1.8-9.7). All-cause mortality
was 7.8% at 30 days, and 16.9% at 1 year, respectively. All-cause mortality at 30 days
was 3.4% in patients with less than median NT-proBNP-ratio, and 14.0% in patients
with more than median NT-proBNP-ratio (p¼0.02). All-cause mortality at 1 year was
7.0% in patients with less than median NT-proBNP-ratio, and 26.8% in those with
more than median NT-proBNP-ratio (p¼0.003). Cumulative survival declined with
increasing quartiles of BNP-ratio (log rank p¼0.001). All patients with a NT-proBNP-
ratio below 1.79 (62/62; 100%) survived at 1 year follow-up. In ROC analysis, NT-
proBNP-ratio signiﬁcantly predicted 30-day (AUC¼0.72; CI¼0.61, 0.83; p¼0.002)
and 1-year all-cause mortality (AUC¼0.71; CI¼0.61, 0.81; p¼0.001). By multivariate
Cox regression analysis including baseline characteristics and NT-proBNP-ratio, both
chronic obstructive pulmonary disease and NT-proBNP-ratio were the only inde-
pendent predictors of all-cause mortality.
Conclusions: NT-proBNP-clinical-activation is associated with increased short- and
long-term mortality after TAVR, and independently predicts all-cause mortality.
Hence, NT-proBNP-clinical-activation should be considered in risk stratiﬁcation for
patients undergoing TAVR.
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of the transcatheter heart valve (THV). Undersizing may result in paravalvular
regurgitation (PVR), while excessive oversizing may result in annular injury. Some
patients have a borderline annular size that ﬁts between two available THV sizes. One
strategy is intentional underexpansion of an oversized THV.
Methods: Thirty one patients underwent TAVR with an intentionally underexpanded
Sapien XT or Sapien 3 THV (Edwards Lifesciences Inc., CA, USA). THVs were
intentionally underexpanded when there was >20% computed tomography (CT)
annular area oversizing or >10% area oversizing with adverse root features. The
deployment balloon was ﬁlled with 5-10% less volume than the manufacturer’s rec-
ommended volume. Transthoracic echocardiography (TTE) and cardiac CT were
performed in all patients immediately post-implant. At 1 year, 31/31 patients (100%)
underwent repeat TTE and 22/31 (71%) underwent repeat CT.
Results: There was no signiﬁcant change in THV hemodynamics or stent size at 1
year. Mean trans-aortic gradient was 124 mmHg immediately post-implant and
126 mmHg at 1 year (p¼0.3). Mean aortic valve area was 1.70.3 cm2 imme-
diately post-implant and 1.60.5 cm2 at 1 year (p¼0.4). PVR was mild or less in
31/31 patients (100%) immediately post-implant and in 30/31 patients (97%) at 1
year. One patient had moderate PVR at 1 year. CT derived stent frame area
immediately post-implant and at 1 year was 4.90.9 cm2 and 5.10.9 cm2
respectively at stent inﬂow (p¼0.05), 5.11.0 cm2 and 5.21.0 cm2 respectively at
mid stent (p¼0.5), 5.30.9 cm2 and 5.20.9 respectively at stent outﬂow (p¼0.5).
There was no signiﬁcant difference in stent frame short and long axis immediately
post-implant versus 1 year, either at the stent inﬂow, mid stent or stent outﬂow (all
p-values >0.05).
Conclusions: There was no signiﬁcant change in THV hemodynamic function and
stent frame expansion 1 year following TAVR with an intentionally underexpanded
balloon-expandable THV. In selected patients in whom excessive oversizing is a
concern, a strategy of intentional underexpansion may reduce the risk of annular
injury without compromising valve performance.
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Background: Transcatheter aortic valve implantation (TAVI) is a minimally invasive
alternative to surgical aortic valve replacement (SAVR) in high risk surgical patients.
Pooled meta-analysis was attempted to analyze the risk of developing permanent heart
block following TAVI.
Methods: All electronic databases were queried for published studies on TAVI and
SAVR. Studies reporting the outcomes of TAVI procedure were included. Exclusion
criteria applied was: studies lacking SAVR as controls, studies comparing trans-apical
versus trans-femoral TAVI procedures and studies not reporting on the outcome of
heart block or pacemaker implantation.
Results: A total of 21 studies with a total of 5061 patients were included in the
study and 2692 of these had TAVI. The risk of permanent heart block necessitating
pacemaker implantation was very high in the patients undergoing TAVI comparedtember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMto SAVR (OR 3.5, 95% CI 2.4 – 5.1). Majority of the pacemaker implantations
were done immediately after the TAVI procedure. Trans-femoral TAVI’s were
associated with higher risk (OR 8.6, 95% CI 3.1 – 28.3) of developing permanent
heart block compared to transapical route (OR 2.4, 95% CI, 1.3 – 4.3). Core Valve
use was associated with a higher risk of developing permanent heart block (OR 2.4,
95% CI 1.6 – 3.6) than Edward Sapiens Valve (OR 1.9, 95% CI 1.2 – 2.8)
compared to SAVR.
Conclusions: Patients undergoing minimally invasive TAVI procedure have a four
times higher risk of developing heart block needing pacemaker implantation compared
to patients undergoing SAVR procedure.
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Background: The Edwards SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA)
transcatheter heart valve ( S3 THV) incorporates a paravalvular sealing system with
an active 3-dimensional coaxial positioning. No comparisons in clinical practice
have been performed with its predecessor, SAPIEN XT (SXT) with regards to
paravalvular aortic regurgitation (PAR), a predictor of future mortality in TAVR
patients.
Methods: All patients implanted with an Edwards XT or S3 THV, from January 2013
to April 2014 in San Rafaelle Scientiﬁc Institute, Milan, Italy, were included in the
current study. PAR was assessed using aortography and transthoracic echocardiog-
raphy after TAVR.
Results: A total of 61 Edwards SAPIEN transfemoral TAVR were performed (14
S3 and 47 SXT). With the exception of higher percentage of baseline moderate/
severe AR in the Sapiens 3 group (20% SXT vs. 64.3% S3, p¼0.002) baseline
demographics did not differ signiﬁcantly between the groups (Table 1). Balloon
aortic valve predilatation was performed more frequently in the SXT group (95.7%
vs. 28.6%, p< 0.001). In both groups similar valve sizes were used (23/26/29mm:
38.3%/48.9%/12.8% S3 vs. 37.7%/35.7%/28.6% SXT, p0.355). Similar was also
the percentage of postdilatation (23.4 % SXT vs. 21.4% S3, p¼0.877). Final
aortography revealed non/trace PAR in 92.9% S3 vs. 17.9% SXT; mild in 7.1%
S3 vs. 67.7% SXT and moderate/severe in 0% S3 and 15.4% SXT (p< 0.001).
Similar results were obtained when comparing ﬁnal echocardiographic assessment
for PAR. There was a trend for a higher device success (as per VARC-2) amongst
S3 patients (100% vs. 83%, p¼0.180).Baseline
Characteristics Total(N¼61)
Edwards
SAPIEN XT
(N¼47)
Edwards
SAPIEN 3
(N¼14)
P-
value
Age (years) 80.27.0 80.477.0 79.367.3 0.607
Female gender 45.90% 51.10% 28.60% 0.138
Diabetes Mellitus 26.20% 27.70% 21.40% 0.642
Previous myocardial
infarction
9.80% 10.60% 7.10% 0.7
Previous PCI 21.30% 21.30% 21.40% 0.99
Previous CABG 21.30% 19.10% 28.60% 0.45
Logistic EuroSCORE
(%)
18.614.9 18.314.9 19.815.4 0.746
STS Score (%) 5.4 (3.6 to
12.0)
6.3 (3.9 to
13.7)
4.4 (3.2 to
10.0)
0.11
Left ventricular
ejection fraction (%)
53.213.3 52.113.7 56.8 0.25
Mean aortic
annulus (mm) CT
23.91.8 23.81.7 24.52.2 0.214
Minimum ilio-
femoral diameter
(mm)
7.01.2 7.21.2 6.61.0 0.156
Aortic valve area
(cm2)
0.701.2 0.650.16 0.790.19 0.016
Aortic mean
gradient (mmHg)
50.314.5 51.215.6 47.610.6 0.426
Aortic regurgitation
 moderate
30.50% 20% 64.30% 0.002
Mitral regurgitation
 moderate
32.20% 33.30% 28.60% 0.739
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regurgitation when compared to its predecessor SXT.
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Background: Procedural technical features of CoreValve implantation have been
shown to affect the short and long-term outcome after Transcatheter Aortic Valve
Implantation (TAVI). The aim of this study was to evaluate the impact of Cor-
eValve implantation depth on the short-term hemodynamic and procedural
characteristics.
Methods: From June 2008 until February 2013, patients who had undergone TAVI
with the CoreValve device, were retrospectively studied. The device implantation
depth was evaluated in ofﬂine analysis by measuring the distance between the lowest
coronary cusp calcium border, as depicted in the post-implantation aortography, and
the lowest edge of the device frame (smaller measured distance indicating higher
implantation depth, see image). The aortic valve regurgitation (AR) was evaluated
after TAVI and classiﬁed as none, mild and moderate. Finally, the necessity of post-
implantation balloon dilatation in order to achieve a better valve expansion was
recorded.
Results: A total of 119 patients (mean age 80.65.3 yrs, 62 males) were ﬁnally
enrolled. The implantation was performed either transfemoraly, or through subcla-
vian route (12 patients). A statistically signiﬁcant difference was found for the
implantation depth between the three post-TAVI aortic regurgitation classiﬁcations
(8.12mm for none AR, 7.95mm for mild and 6.27mm for moderate AR, p¼0.046),
indicating increased AR with higher device implantation. Similarly, patients who
underwent balloon post-dilatation, had statistical signiﬁcant higher implantation
depth compared with those who didn’t (6.393.2mm vs 8.142.5mm, p¼0.012).
The implantation depth remained an independent predicting factor of balloon post-
dilatation necessity in multivariate logistic regression [OR:0.775 (0.64-0.938),
p¼0.009].
Conclusions: The CoreValve device implantation depth is strongly correlated with the
post-implantation observed aortic regurgitation, as well as with the necessity of
balloon post-dilatation. It seems that, concerning hemodynamic short-term outcome,
operators should be even more careful in device implantation depth ensuring the
optimal positioning.
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Background: In-stent pre-cusp ﬂow acceleration and its importance in the accurate
echo assessment of the Sapien valve are well recognized with stent and valve cusps
contributing to overall valve gradients. The echo ﬂow features of the CoreValve have
not been previously reported.
Methods: Pre-stent (P-S) and in-stent pre-cusp (I-SPC) CoreValve velocities were
measured in 17 consecutive CoreValve pts. Valve sizes (mm) were 26(n¼4),
29(n¼6), and 31(n¼7). Pulsed-wave (PW) Doppler velocity time integral (VTI) was
recorded with sample volume placement at 2 levels: immediately apical to the stent
(P-S) and within the stent just apical to the valve cusps (I-SPC). Effective oriﬁce
area (EOA) ¼ (LVOT CSA X LVOT VTI)/AV VTI and Doppler velocity index
(DVI) ¼ LVOT VTI/AV VTI were calculated using both the P-S and I-SPC for
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